Analytical Teardowns
The cost of chasing validated science: how Pfizer overpays when it needs certainty
Pfizer has spent $88 billion on external innovation since 2018. Majority of that capital sits in just four deals and 37% in one. Jump into the dissection of the dealmaker narrative to find out if this theory holds true for Pfizer.